Treatment Consideration in Postmenopausal Osteoporosis Patients at Imminent Fracture Risk
Osteoporosis is the most common metabolic bone disease and constitutes a major public health problem all over the world. Most international clinical practice guidelines have conventionally positioned the class of antiresorptive drugs, the bisphosphonates, as the first-line medical therapy for the ma...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
World Scientific Publishing
2022-06-01
|
| Series: | Journal of Clinical Rheumatology and Immunology |
| Subjects: | |
| Online Access: | https://www.worldscientific.com/doi/10.1142/S266134172230004X |
| _version_ | 1811344032227393536 |
|---|---|
| author | Tai Pang Ip |
| author_facet | Tai Pang Ip |
| author_sort | Tai Pang Ip |
| collection | DOAJ |
| description | Osteoporosis is the most common metabolic bone disease and constitutes a major public health problem all over the world. Most international clinical practice guidelines have conventionally positioned the class of antiresorptive drugs, the bisphosphonates, as the first-line medical therapy for the management of postmenopausal osteoporosis. With the clinical development of more potent antiresorptive drugs as well as bone-forming drugs, more therapeutic options with different mechanisms of action, therapeutic efficacies, and adverse effect profiles are currently available. Bone-forming drugs have demonstrated a faster and better protection to patients with osteoporosis such that clinical management decisions should position their prioritized use in patients with a very high fracture risk. This article provides a review on the preferential selection of bone-forming drugs for management of postmenopausal osteoporosis in patients with imminent fracture risk. |
| first_indexed | 2024-04-13T19:40:37Z |
| format | Article |
| id | doaj.art-f42bcf9084d9466ba84b480f753dbe7b |
| institution | Directory Open Access Journal |
| issn | 2661-3417 2661-3425 |
| language | English |
| last_indexed | 2024-04-13T19:40:37Z |
| publishDate | 2022-06-01 |
| publisher | World Scientific Publishing |
| record_format | Article |
| series | Journal of Clinical Rheumatology and Immunology |
| spelling | doaj.art-f42bcf9084d9466ba84b480f753dbe7b2022-12-22T02:32:55ZengWorld Scientific PublishingJournal of Clinical Rheumatology and Immunology2661-34172661-34252022-06-0122Supp01101910.1142/S266134172230004XTreatment Consideration in Postmenopausal Osteoporosis Patients at Imminent Fracture RiskTai Pang Ip0Department of Medicine, Tung Wah Hospital, Hong Kong, ChinaOsteoporosis is the most common metabolic bone disease and constitutes a major public health problem all over the world. Most international clinical practice guidelines have conventionally positioned the class of antiresorptive drugs, the bisphosphonates, as the first-line medical therapy for the management of postmenopausal osteoporosis. With the clinical development of more potent antiresorptive drugs as well as bone-forming drugs, more therapeutic options with different mechanisms of action, therapeutic efficacies, and adverse effect profiles are currently available. Bone-forming drugs have demonstrated a faster and better protection to patients with osteoporosis such that clinical management decisions should position their prioritized use in patients with a very high fracture risk. This article provides a review on the preferential selection of bone-forming drugs for management of postmenopausal osteoporosis in patients with imminent fracture risk.https://www.worldscientific.com/doi/10.1142/S266134172230004XOsteoporosisImminent Fracture RiskAntiresorptive DrugsBone-Forming Drugs |
| spellingShingle | Tai Pang Ip Treatment Consideration in Postmenopausal Osteoporosis Patients at Imminent Fracture Risk Journal of Clinical Rheumatology and Immunology Osteoporosis Imminent Fracture Risk Antiresorptive Drugs Bone-Forming Drugs |
| title | Treatment Consideration in Postmenopausal Osteoporosis Patients at Imminent Fracture Risk |
| title_full | Treatment Consideration in Postmenopausal Osteoporosis Patients at Imminent Fracture Risk |
| title_fullStr | Treatment Consideration in Postmenopausal Osteoporosis Patients at Imminent Fracture Risk |
| title_full_unstemmed | Treatment Consideration in Postmenopausal Osteoporosis Patients at Imminent Fracture Risk |
| title_short | Treatment Consideration in Postmenopausal Osteoporosis Patients at Imminent Fracture Risk |
| title_sort | treatment consideration in postmenopausal osteoporosis patients at imminent fracture risk |
| topic | Osteoporosis Imminent Fracture Risk Antiresorptive Drugs Bone-Forming Drugs |
| url | https://www.worldscientific.com/doi/10.1142/S266134172230004X |
| work_keys_str_mv | AT taipangip treatmentconsiderationinpostmenopausalosteoporosispatientsatimminentfracturerisk |